← Back to Clinical Trials
Recruiting NCT03160274

NCT03160274 Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03160274
Status Recruiting
Phase
Sponsor The University of Texas Health Science Center at San Antonio
Condition Pheochromocytoma
Study Type OBSERVATIONAL
Enrollment 2,000 participants
Start Date 2005-10-19
Primary Completion 2030-12-31

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Genetic screening

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2,000 participants in total. It began in 2005-10-19 with a primary completion date of 2030-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical decisions. However, a mutation is not found in all cases. The aims of this proposal are to: 1) to map gene(s) involved in pheochromocytoma, and 2) identify genotype-phenotype correlations in patients with pheochromocytoma/paraganglioma of various genetic origins.

Eligibility Criteria

Inclusion Criteria: * diagnosis of pheochromocytoma and or paraganglioma * family member with diagnosis of pheochromocytoma and or paraganglioma * diagnosis of a pheochromocytoma- and or paraganglioma-associated condition * family member with diagnosis of a pheochromocytoma- and or paraganglioma-associated condition Exclusion Criteria: * unconfirmed diagnosis of pheochromocytoma and/or paraganglioma or associated condition

Contact & Investigator

Central Contact

Patricia L Dahia, MD,PhD

✉ dahia@uthscsa.edu

📞 2105674866

Principal Investigator

Patricia L Dahia, MD, PhD

PRINCIPAL INVESTIGATOR

The University of Texas Health Science Center at San Antonio

Frequently Asked Questions

Who can join the NCT03160274 clinical trial?

This trial is open to participants of all sexes, studying Pheochromocytoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03160274 currently recruiting?

Yes, NCT03160274 is actively recruiting participants. Contact the research team at dahia@uthscsa.edu for enrollment information.

Where is the NCT03160274 trial being conducted?

This trial is being conducted at San Antonio, United States.

Who is sponsoring the NCT03160274 clinical trial?

NCT03160274 is sponsored by The University of Texas Health Science Center at San Antonio. The principal investigator is Patricia L Dahia, MD, PhD at The University of Texas Health Science Center at San Antonio. The trial plans to enroll 2,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology